InsidersTradesSigma
Follow the Immunome, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €3.1bn. The latest transaction was disclosed on 6 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: ABHMC II, LLC. The full history is free.
Analysts rate Immunome, Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$36.31.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Immunome, Inc. 是一家生物制药公司，专注于开发用于癌症和其他疾病的抗体疗法。该公司利用其抗体发现平台来识别创新的治疗候选药物。